Stay updated on Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial

Sign up to get notified when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T15:01:12.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the page. The funding-lapse/open-status notice and the previous Revision: v3.4.1 entry were removed.
    Difference
    0.5%
    Check dated 2026-02-11T02:07:30.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding and operating status, and updated the page version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-03T23:57:49.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a glossary toggle and new QC/status meta labels (Last Update Submitted that Met QC Criteria and Revision: v3.4.0). Replaced the previous labels Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-28T00:00:40.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4 on the page; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:25:00.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    A consolidated 'Locations' section appears, including California and Georgia sites, replacing the separate 'California Locations' and 'Georgia Locations' subsections; the footer 'HHS Vulnerability Disclosure' link has been removed.
    Difference
    0.4%
    Check dated 2025-12-23T17:13:23.000Z thumbnail image

Stay in the know with updates to Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.